Inflammatory and mucus secretion pathway proteins

Inflammatory and mucus secretion pathway proteins refer to a coordinated network of signaling molecules and effectors that drive airway inflammation and excessive mucus production in chronic respiratory diseases. The pathway is primarily initiated by Type 2 cytokines, specifically interleukin-4 (IL-4) and interleukin-13 (IL-13), which bind to the IL-4 receptor alpha (IL-4Rα) complex (Nature Reviews Drug Discovery, 2016). This binding activates downstream transcription factors like STAT6 and SPDEF, which promote the transformation of airway epithelial cells into mucus-producing goblet cells, a process known as goblet cell metaplasia (Journal of Experimental Medicine, 2002). The resulting overproduction of gel-forming mucins, such as MUC5AC, leads to airway plugging and reduced lung function (New England Journal of Medicine, 2010). Therapeutic interventions targeting this pathway, including monoclonal antibodies like dupilumab and lebrikizumab, aim to interrupt this signaling cascade to alleviate both the inflammatory burden and the clinical symptoms of mucus hypersecretion in patients with asthma and COPD (New England Journal of Medicine, 2011).

Other names

Type 2 inflammatory pathwayIL-13/MUC5AC signaling axisAirway mucus hypersecretion pathwayTh2-mediated mucus production pathway

Inhibition of Type 2 cytokines (IL-4, IL-13) or their receptors to block the signaling cascade that induces goblet cell hyperplasia and MUC5AC gene expression.